DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
+10.93%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$355M
AUM Growth
+$355M
(-4.5%)
Cap. Flow
-$38.9M
Cap. Flow
% of AUM
-10.97%
Top 10 Holdings %
Top 10 Hldgs %
50.26%
Holding
91
New
4
Increased
16
Reduced
26
Closed
11
Top Buys
| 1 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$8.48M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$4.38M |
| 3 |
Biohaven
BHVN
|
$3.32M |
| 4 |
BioCryst Pharmaceuticals
BCRX
|
$2.88M |
| 5 |
KalVista Pharmaceuticals
KALV
|
$2.44M |
Top Sells
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$16.6M |
| 2 |
MediWound
MDWD
|
$16.5M |
| 3 |
CBAY
Cymabay Therapeutics
CBAY
|
$9.61M |
| 4 |
AERI
Aerie Pharmaceuticals, Inc.
AERI
|
$4.65M |
| 5 |
89bio
ETNB
|
$4.21M |
Sector Composition
| 1 | Healthcare | 81.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
SPDR S&P Biotech ETF
XBI
$5.07B
| $47M | 13.23% | 566,000 | – | – |
|
2
Stereotaxis
STXS
$261M
| $28.3M | 7.98% | 13,680,554 | – | – |
|
3
Ascendis Pharma
ASND
$11.8B
| $15.9M | 4.48% | 130,212 -5,500 | -4% | -$672K |
|
|
KRTX
4
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $14.2M | 3.99% | 72,027 +43,141 | +149% | +$8.48M |
|
5
iShares Biotechnology ETF
IBB
$5.6B
| $13.5M | 3.79% | 102,500 | – | – |
|
|
ISEE
6
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $13M | 3.65% | 605,975 +204,499 | +51% | +$4.38M |
|
7
Xenon Pharmaceuticals
XENE
$2.98B
| $12.5M | 3.51% | 316,092 -59,131 | -16% | -$2.33M |
|
|
BPMC
8
DELISTED
Blueprint Medicines
BPMC
| $11.4M | 3.22% | 261,235 | – | – |
|
9
Revolution Medicines
RVMD
$7.1B
| $11.4M | 3.21% | 477,785 -2,000 | -0.4% | -$47.6K |
|
10
Syndax Pharmaceuticals
SNDX
$1.41B
| $11.4M | 3.2% | 447,073 +91,586 | +26% | +$2.33M |
|
11
Neurocrine Biosciences
NBIX
$13.8B
| $8.73M | 2.46% | 73,121 -7,034 | -9% | -$840K |
|
12
IDEAYA Biosciences
IDYA
$2.15B
| $8.51M | 2.4% | 468,358 -70,203 | -13% | -$1.28M |
|
13
Cytokinetics
CYTK
$4.23B
| $8.43M | 2.37% | 183,995 | – | – |
|
14
DexCom
DXCM
$29.5B
| $7.65M | 2.15% | 67,552 -5,000 | -7% | -$566K |
|
|
SAGE
15
DELISTED
Sage Therapeutics
SAGE
| $6.88M | 1.94% | 180,306 | – | – |
|
16
Edgewise Therapeutics
EWTX
$1.51B
| $6.86M | 1.93% | 766,843 -14,269 | -2% | -$128K |
|
17
Nurix Therapeutics
NRIX
$714M
| $6.22M | 1.75% | 566,695 | – | – |
|
18
Adicet Bio
ACET
$59.9M
| $5.65M | 1.59% | 631,554 -304,212 | -33% | -$2.72M |
|
19
Fate Therapeutics
FATE
$120M
| $5.56M | 1.57% | 550,940 +11,000 | +2% | +$111K |
|
|
20
Biohaven
BHVN
$1.63B
| $5.46M | 1.54% | 393,113 +239,549 | +156% | +$3.32M |
|
|
MORF
21
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $5.23M | 1.47% | 195,467 | – | – |
|
22
Alector
ALEC
$238M
| $4.91M | 1.38% | 532,438 | – | – |
|
23
Viking Therapeutics
VKTX
$3.04B
| $4.9M | 1.38% | 521,553 -30,847 | -6% | -$290K |
|
24
Apellis Pharmaceuticals
APLS
$3.48B
| $4.31M | 1.22% | 83,446 +17,500 | +27% | +$905K |
|
25
Merus
MRUS
$4.98B
| $4.18M | 1.18% | 269,893 -7,000 | -3% | -$108K |
|